NAMA : Gigih Sanjaya Putra

NPM : 1822011029
MATKUL : Metode Penelitian
DOSEN : DR. Rudi Natamihardja, DEA

NO. JUDUL ARTIKEL NAMA TAHUN ISI ABSTRAK KESIMPULAN

PENGARANG TERBIT
1. Serial interval of Hiroshi Nishiura, 2020 Objective: Kesimpulan yang saya dapat
novel coronavirus Natalie M.Linton (Q1) To estimate the serial interval of novel adalah bahwa kejadian interval
(COVID-19) Andrei, coronavirus (COVID-19) from information on covid 19 yang diambil dari data
infections R.Akhmetzhanov 28 infector-infectee pairs. primer (carier) dan data sekunder
Methods: (terinfeksi) menunjukan bahwa
We collected dates of illness onset for interval kejadian covid 19 lebih
primary cases (infectors) and secondary dekat/pendek dari masa
cases (infectees) from published research inkubasinya. Hal ini menunjukan
articles and case investigation reports. We bahwa sebagian proses
subjectively ranked the credibility ofthe data penularan dapat terjadi sebelum
and performed analyses on both the full timbulnya penyakit.
dataset (n = 28) and a subset of pairs with
highest certainty in reporting (n = 18). In
addition, we adjust for right truncation of the
data as the epidemic is stillin its growth
phase.
 Results:
Accounting for right truncation and analyzing
all pairs, we estimated the median serial
interval at 4.0 days (95% credible interval
[CrI]: 3.1, 4.9). Limiting our data to only the
most certain pairs, the median serial interval
was estimated at 4.6 days (95% CrI: 3.5,
5.9).
Conclusions:
The serial interval of COVID-19 is close to or
shorter than its median incubation period.
This suggests that a substantial proportion of
secondary transmission may occur prior to
illness onset. The COVID-19 serial interval is
also shorter than the serial interval of severe
acute respiratory syndrome (SARS),
indicating that calculations made using the
SARS serial interval may introduce bias
2. The effectiveness Biao Tang, et.all 2020 Objectives: Kesimpulan yang saya dapat
of quarantine and (Q1) Since January 23rd 2020, stringent adalah kejadian covid di China
isolation measures for controlling the novel terus meningkat, maka langkah-
determine the coronavirus epidemicshave been gradually langkah ketat mulai diterapkan
trend of the enforced and strengthened in mainland untuk mengendalikan epidemi
COVID-19 China. The detection and diagnosis corona. Deteksi dini dan
epidemics in the havebeen improved as well. However, the diagnosis juga meningkat,
final phase of the daily reported cases staying in a high level sehingga sebagian besar kasus
current out break make the epidemics trend prediction difficult. yang terinfeksi telah dikarantina
in China Methods: dan diisolasi.
Since the traditional SEIR model does not
evaluate the effectiveness of control
strategies, a novel model in line with the
current epidemics process and control
measures was proposed, utilizing multi
source data sets including cumulative
number of reported, death, quarantined and
suspected cases.
Results:
Results show that the trend of the epidemics
mainly depends on quarantined and
suspected cases. The predicted cumulative
numbers of quarantined and suspected
cases nearly reached static statesand their
inflection points have already been achieved,
with the epidemics peak coming soon. The
estimated effective reproduction numbers
using model-free and model-based methods
 are decreasing, as well as new infections,
while new reported cases are increasing.
Most infected cases have been quarantined
or put in suspected class, which has been
ignored in existing models.
Conclusions:
The uncertainty analyses reveal that the
epidemics is still uncertain and it is important
to continue enhancing the quarantine and
isolation strategy and improving the
detection rate in main land China
3. Prevalence of Jing Yang, et.all 2020 Background: Kesimpulan yang saya dapat
comorbidities and (Q1) An outbreak of coronavirus disease 2019 adalah gejala klinis yang paling
its effects in (COVID-19) occurred in Wuhan, China; the umum adalah demam (91,3%,
patients infected epidemic is more widespread than initially 95% CI: 86-97%), diikuti oleh
with SARS-CoV- estimated, with cases now confirmed in batuk (67,7%, 95% CI: 59-76%),
2: a systematic multiple countries. kelelahan (51,0%, 95% CI: 34-
review and meta Aims: The aim of this meta-analysis was to 68%) dan dispnea (30,4%, 95%
analysis assess the prevalence of comorbidities in the CI: 21-40%). Komorbiditas yang
severe acute respiratory syndrome paling umum adalah hipertensi
coronavirus 2 (SARS-CoV-2) infected (21,1%, 95% CI: 13,0–27,2%)
patients and the risk of underlying diseases dan diabetes (9,7%, 95% CI: 7,2-
insevere patients compared to non-severe 12,2%), diikuti oleh penyakit
patients. kardiovaskular (8,4%, 95% CI:
Methods: 3,8-13,8) %) dan penyakit sistem
A literature search was conducted using the pernapasan (1,5%, 95% CI: 0,9-
data bases PubMed, EMBASE, and Web of 2,1%). Ketika dibandingkan
Science through February 25, 2020. Odds antara pasien yang parah dan
ratios (ORs) and 95% confidence intervals yang tidak parah, hipertensi,
(CIs) were pooled usingrandom-effects penyakit sistem pernapasan, dan
models. penyakit kardiovaskular adalah
Results: 2,36 (95% CI: 1,46-3,83), 2,46
Seven studies were included in the meta- (95% CI: 1,76-3,44) dan 3,42
analysis, including 1 576 infected patients. (95%) CI: 1,88-6,22) masing-
The results showed the most prevalent masing. Maka, prevalensi
clinical symptom was fever (91.3%, 95% CI: komorbiditas pada pasien
86–97%), followed by cough (67.7%, 95% COVID-19 menunjukan bahwa
CI: 59–76%), fatigue (51.0%, 95% CI: 34– penyakit yang mendasarinya,
68%) and dyspnea (30.4%, 95% CI: 21– antara lain hipertensi, penyakit
40%). The most prevalent comorbidities sistem pernapasan, dan penyakit
were hypertension (21.1%, 95% CI: 13.0– kardiovaskular, menjadi faktor
27.2%) and diabetes (9.7%, 95% CI: 7.2– risiko untuk pasien menjadi parah
12.2%), followed by cardiovascular disease dibandingkan dengan pasien
(8.4%, 95% CI: 3.8–13.8%) and respiratory yang tidak mempunyai riwayat
system disease (1.5%,95% CI: 0.9–2.1%). penyakit hipertensi, penyakit
When compared between severe and non- sistem pernafasan dan
 severe patients, the pooled OR of kardiovaskular.
hypertension, respiratory system disease,
and cardiovascular disease were 2.36 (95%
CI: 1.46–3.83), 2.46 (95% CI: 1.76–3.44)
and 3.42 (95% CI: 1.88–6.22) respectively.
Conclusion: We assessed the prevalence of
comorbidities in the COVID-19 patients and
found that underlying disease, including
hypertension, respiratory system disease
and cardiovascular disease, maybe risk
factors for severe patients compared with
non-severe patients.
4. COVID-19: Kam Wa Chan, 2020 As of 22 February 2020, more than 77662 Kesimpulan yang saya dapat
An Update on the Vivian Taam (Q1) cases of confirmed COVID-19 have been adalah angka kejadian kasus
Epidemiological, Wong documented globally with over 2360 deaths. covid 19 di China lebih dari
Clinical, Common presentations of confirmed cases 77662 kasus yang terkonfirmasi
Preventive and include fever, fatigue, dry cough, upper dan telah didokumentasikan
Therapeutic airway congestion, sputum production, secara global dengan lebih dari
Evidence and shortness of breath, myalgia/arthralgia with 2.360 kematian. Presentasi
Guidelines of lymphopenia, prolonged prothrombin time, umum dari kasus yang
Integrative elevated C-reactive protein, and elevated dikonfirmasi termasuk demam,
Chinese–Western lactate dehydrogenase. The reported kelelahan, batuk kering, kongesti
Medicine for the severe/critical case ratio is approximately 7– jalan napas atas, produksi dahak,
Management of 10% and median time to intensive care sesak napas, mialgia/artralgia
2019 Novel admission is 9.5–10.5 days with mortality of dengan limfopenia, waktu
Coronavirus around 1–2% varied geographically. Similar protrombin yang lama,
Disease to outbreaks of other newly identified virus, peningkatan protein C-reaktif,
there is no proven regimen from peningkatan protein laktat
conventional medicine and most reports dehidrogenase. Rasio kasus
managed the patients with lopinavir/ritonavir, berat/kritis yang dilaporkan
ribavirin, beta-interferon, glucocorticoid and adalah sekitar 7-10% dan waktu
supportive treatment with remdesivir rata-rata untuk perawatan intensif
undergoing clinical trial. In China, Chinese adalah 9,5-10,5 hari dengan
medicine is proposed as a treatment option mortalitas sekitar 1-2% bervariasi
by national and provincial guidelines with secara geografis. Mirip dengan
substantial utilization. We reviewed the latest wabah virus baru lainnya yang
national and provincial clinical guidelines, diidentifikasi, tidak ada rejimen
retrospective cohort studies, and case series yang terbukti dari pengobatan
regarding the treatment of COVID-19 by konvensional dan sebagian besar
add-on Chinese medicine. We have also laporan mengatur pasien dengan
reviewed the clinical evidence generated lopinavir / ritonavir, ribavirin, beta-
from SARS and H1N1 management with interferon, glukokortikoid dan
hypothesized mechanisms and latest in silico pengobatan suportif dengan
findings to identify candidate Chinese remdesivir yang sedang
medicines for the consideration of possible menjalani uji klinis. Di Cina,
trials and management. Given the paucity of pengobatan Tiongkok diusulkan
strongly evidence-based regimens, the sebagai pilihan pengobatan oleh
available data suggest that Chinese pedoman nasional dan provinsi
medicine could be considered as an dengan pemanfaatan yang
adjunctive therapeutic option in the substansial. Maka, dilakukan
management of COVID-19. peninjauan pedoman klinis
nasional dan provinsi terbaru,
studi kohort retrospektif, dan seri
kasus mengenai pengobatan
COVID-19 dengan tambahan
pengobatan Tiongkok. Kemudian,
dilakukan peninjauan bukti klinis
dari manajemen SARS dan H1N1
dengan mekanisme hipotesis dan
temuan terbaru dalam silico untuk
mengidentifikasi kandidat obat-
obatan Cina untuk pertimbangan
uji coba dan manajemen. Namun,
karena kurangnya rejimen
berbasis bukti, data yang tersedia
menunjukkan bahwa pengobatan
Tiongkok dapat dianggap
sebagai pilihan terapi tambahan
dalam manajemen COVID-19.